Posted by Michael Wonder on 29 Apr 2021
CCRM and Amgen partner to advance emerging medical innovations
29 April 2021 - New fund to support regenerative medicine discoveries with high potential impact for patients.
New regenerative medicine discoveries, including cell and gene therapies, will never reach patients without access to the funding, expertise and other specialised support that are required to move along the commercialisation pathway.
To address this need, CCRM, a leader in developing and commercialising regenerative medicine-based technologies and cell and gene therapies, and Amgen are announcing a multi-year fund, for early-stage regenerative medicine based technologies and therapies to benefit patients and the health-care system.
The collaboration is made up of equivalent investments from CCRM and Amgen.
